Year: 2010
Type: review
Abstract: Alzheimer's disease (AD) is the major cause of dementia in the elderly, leading to memory loss and cognitive decline. The mechanism underlying onset of the disease has not been fully elucidated. However, characteristic pathological manifestations include extracellular accumulation and aggregation of the amyloid beta-peptide (Abeta) into plaques and intracellular accumulation and aggregation of hyperphosphorylated tau, forming neurofibrillary tangles. Despite extensive research worldwide, no disease modifying treatment is yet available. In this review, we focus on gene therapy as a potential treatment for AD, and summarize recent work in the field, ranging from proof-of-concept studies in animal models to clinical trials. The multifactorial causes of AD offer a variety of possible targets for gene therapy, including two neurotrophic growth factors, nerve growth factor and brain-derived neurotrophic factor, Abeta-degrading enzymes, such as neprilysin, endothelin-converting enzyme and cathepsin B, and AD associated apolipoprotein E. This review also discusses advantages and drawbacks of various rapidly developing virus-mediated gene delivery techniques for gene therapy. Finally, approaches aiming at down-regulating amyloid precursor protein (APP) and beta-site APP cleaving enzyme 1 levels by means of siRNA-mediated knockdown are briefly summarized. Overall, the prospects appear hopeful that gene therapy has the potential to be a disease modifying treatment for AD.
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: Alzheimer's disease, gene therapy, disease modification, amyloid-beta, tau hyperphosphorylation, neurofibrillary tangles, nerve growth factor, brain-derived neurotrophic factor, neprilysin, endothelin-converting enzyme, cathepsin B, apolipoprotein E, amyloid precursor protein, beta-site APP-cleaving enzyme 1, siRNA knockdown, clinical trials
Open Access status: bronze
Awards: ネプリライシンの活性低下による神経病理と活性増強機構の解析, The roles of proteolytic systems in brain aging, Gene therapy for Alzheimer's disease by viral vector-mediated neprilysin, an Aβ-degrading enzyme, gene transfer, ネプリライシンの活性低下に伴うシナプス機能障害と発現調節機構の解析, ピラミッド複合体と古代エジプト王権, A alzheimer disease mouse model by decrease in cerebral amyloid degradation and functional analysis, Identification of the major in vivo ABl-42-degrading catabolic-system in brain parenchyma.
OpenAlex ID: W2082185331
